SNCA and Parkinson disease: The second most co-cited reference was a study by Junn E et al, published in Proceedings of the National Academy of Sciences of the United States of America.[12] Since PD is characterized by the accumulation of α-synuclein in Lewy bodies, targeting this pathogenic protein represents a promising therapeutic strategy.